Alnylam Pharmaceuticals (ALNY, Biotech) Stock Valuation & Fair Value
Mixed on our testsAlnylam Pharmaceuticals (ALNY, Biotech) trades at a current P/E of 9.0, a multiple its historical normal P/E is too distorted to compare with, with a forward growth estimate of -20.2%. Analysts' one-year estimates have been hit 27% of the time.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
The historical normal P/E published for Alnylam Pharmaceuticals is 170.7, more than six times its current multiple. A gap that wide comes from the company's earnings history rather than from its price, so this page quotes no premium or discount against it.
- Price $155.94 at the Nov 6 close, 23.9% below the 20-day average ($204.95) and 31.8% below the 50-day ($228.57).
- RSI (14) at 21.9.
- 52-week range $155.94 to $473.29: the price is 67.1% below the high and at the low.
The Street vs SeerForecast
Wall Street's mean price target for ALNY is $310.89 across 27 analysts, 99.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Profitable in only 1 of the last 3 reported years
- Long-term debt is over half its capital (67%)
- Negative growth forecast
- Misses analyst estimates often (82%)
Verdict history
tickerseer's rating moved from favorable on our tests (2026-07-25) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 32 readings
Frequently asked questions
Is Alnylam Pharmaceuticals stock overvalued?
Alnylam Pharmaceuticals trades at a current P/E of 9.0. Its published historical normal P/E is 170.7, more than six times that, so there is no meaningful premium or discount to quote. tickerseer currently rates it mixed on our tests.
What is Alnylam Pharmaceuticals's fair value and PEG?
Alnylam Pharmaceuticals trades at a current P/E of 9.0, a forward growth estimate of -20.2%.
Has tickerseer's rating of Alnylam Pharmaceuticals changed?
tickerseer's rating moved from favorable on our tests (2026-07-25) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Alnylam Pharmaceuticals?
The mean Wall Street price target for Alnylam Pharmaceuticals is $310.89 across 27 analysts, 99.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.